JP2023549067A5 - - Google Patents

Info

Publication number
JP2023549067A5
JP2023549067A5 JP2023525485A JP2023525485A JP2023549067A5 JP 2023549067 A5 JP2023549067 A5 JP 2023549067A5 JP 2023525485 A JP2023525485 A JP 2023525485A JP 2023525485 A JP2023525485 A JP 2023525485A JP 2023549067 A5 JP2023549067 A5 JP 2023549067A5
Authority
JP
Japan
Prior art keywords
antibody
cov
sars
spike protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549067A (ja
Filing date
Publication date
Priority claimed from GBGB2017058.5A external-priority patent/GB202017058D0/en
Application filed filed Critical
Publication of JP2023549067A publication Critical patent/JP2023549067A/ja
Publication of JP2023549067A5 publication Critical patent/JP2023549067A5/ja
Pending legal-status Critical Current

Links

JP2023525485A 2020-10-27 2021-10-27 Sars-cov-2に対する抗体およびその使用 Pending JP2023549067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2017058.5 2020-10-27
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549067A JP2023549067A (ja) 2023-11-22
JP2023549067A5 true JP2023549067A5 (enExample) 2024-11-05

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525485A Pending JP2023549067A (ja) 2020-10-27 2021-10-27 Sars-cov-2に対する抗体およびその使用

Country Status (12)

Country Link
US (1) US20250026813A1 (enExample)
EP (1) EP4237442A1 (enExample)
JP (1) JP2023549067A (enExample)
KR (1) KR20230113295A (enExample)
CN (1) CN117396501A (enExample)
AU (1) AU2021369450A1 (enExample)
CA (1) CA3199594A1 (enExample)
CO (1) CO2023006684A2 (enExample)
GB (1) GB202017058D0 (enExample)
IL (1) IL302244A (enExample)
MX (1) MX2023004869A (enExample)
WO (1) WO2022090353A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
MX2022014852A (es) 2020-06-03 2023-02-01 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2.
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN121002058A (zh) * 2022-12-09 2025-11-21 艾布维兹生物公司 针对SARS-CoV-2及其变体的抗体或其片段
KR20250143366A (ko) * 2023-01-10 2025-10-01 사나 바이오테크놀로지, 인크. Cd19 특이적 항체 작제물 및 이의 조성물
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CA2931641C (en) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof

Similar Documents

Publication Publication Date Title
KR102184343B1 (ko) 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법
DK2807192T3 (en) COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2021521843A (ja) 最適化された抗tl1a抗体
CN118141914A (zh) 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
KR20150094621A (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
TW202334429A (zh) Sars-cov-2棘蛋白特異性抗體及其用途
WO2023129928A2 (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
IL262441B2 (en) Methods for treating diseases in which il-13 activity is harmful using antibodies to il-13
JP2017507131A5 (enExample)
CN118696061A (zh) Nectin细胞黏附分子4之特异性抗体及其用途
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
JP2025507595A5 (enExample)
US10689441B2 (en) Anti—TLR4 antibodies and methods of use thereof
KR20180105642A (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
TW202214297A (zh) 用於治療疼痛之結合TGF-α及表皮調節素(EPIREGULIN)之抗體
CN116178530A (zh) 抗体在治疗SARS-CoV-2感染的用途
CN104797597A (zh) 针对胞壁肽的单克隆抗体
US20170038381A1 (en) Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
JP2022527790A5 (enExample)
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JP2024543911A5 (enExample)
WO2018203289A1 (en) Methods of selectively treating asthma using il-17 antagonists
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療